One of the most difficult challenges of oncology is to improve methods for early tumor
detection, which is crucial for the success of cancer therapy and greatly improves the …

In vivo assessment of the outcome of cancer therapy is hampered by the paucity of imaging
probes that target tumors specifically and noninvasively. The importance of such probes …

Alterations in mucin expression and glycosylation are associated with cancer development.
Underglycosylated mucin-1 (uMUC1) is overexpressed in most malignant adenocarcinomas …

The mucin MUC1 is typically aberrantly glycosylated by epithelial cancer cells manifested by
truncated O-linked saccharides. The resultant glycopeptide epitopes can bind cell surface …

Abstract The epithelial mucin 1 (MUC1) is an accepted serum tumor marker and cellular
tumor antigen. We discuss recent views on the difference (s) between normal and tumor …

Protein glycosylation often changes during cancer development, resulting in the expression
of cancer-associated carbohydrate antigens. In particular mucins such as MUC1 are subject …

Autoantibodies to cancer antigens hold promise as biomarkers for early detection of cancer.
Proteins that are aberrantly processed in cancer cells are likely to present autoantibody …

The overexpression and aberrant glycosylation of MUC1 is associated with a wide variety of
cancers, making it an ideal target for immunotherapeutic strategies. This review highlights …

For more than a decade, tumor immunologists have focused their efforts on discovering
tumor-associated antigens, as a first step toward the design of an effective cancer vaccine …

Mucin-type O-glycans are found on mucins as well as many other glycoproteins. The
initiation step in synthesis is catalyzed by a large family of polypeptide GalNAc-transferases …